Gradalis today revealed early details of a study indicating that its personalized cancer vaccine could delay recurrences of ovarian cancer in advanced stage patients by at least a year.
The Dallas-based startup, founded in 2005, presented results of a phase II... Read more »
OSI Pharmaceuticals became the home-grown beacon of Long Island, NY’s biotech scene behind the lung cancer drug erlotinib (Tarceva), which was so successful that led Japan’s Astellas Pharma to buy the company outright in a $4 billion deal in May 2010.... Read more »
Yesterday, we ran the first part of a wide-ranging interview with Henri Termeer, the legendary biotech entrepreneur and former CEO of Cambridge, MA-based Genzyme. He spoke about what kinds of startups he likes to get involved in, the trend toward... Read more »
For Radius Health, it’s all about September.
That’s when the Cambridge, MA-based biotech will unveil the mid-stage data on a version of its experimental osteoporosis drug, BAO58, which is administered through a patch affixed to the skin.
CEO Michael Wyzga makes... Read more »
Henri Termeer could have easily faded away into obscurity a couple years ago. The biotech pioneer could have relaxed at his oceanside home in Maine, played a little golf. Or, if he wanted, he could have made loads of money at... Read more »
It was a busy week of big promise and big moves for biotechs on the East Coast. One biotech added to a string of partnerships and awaits results from a key mid-stage study for one of its own drugs. Another signed... Read more »
Dendreon has made a habit of disappointing investors, and it did so again today.
The Seattle-based biotech company (NASDAQ: DNDN) said today it generated $67.6 million in first quarter sales of sipuleucel-T (Provenge), down a whopping 17.6 percent from the... Read more »
Biotech stars can rise and fall on the key decision of whether or not to “go it alone” and develop their drugs without the help of Big Pharma—it’s a risk that can either make or break a company. But Regado BioSciences,... Read more »
Amid the hectic pace of earnings releases, we saw a number of partnership agreements and other developments coming out of San Diego’s life sciences community. Here’s my wrap-up.
—Shares of San Diego-based Receptos (NASDAQ: RCPT), a biotech developing new treatments... Read more »